Policy year pharmaceutical enterprises deeply affected

Recently, Jiangsu Provincial Drug Administration announced that Yangzhou Pharmaceutical was incorporated by Jiangsu Lianhuan pharmaceutical industry It is understood that upon the written application of Yangzhou Pharmaceutical Co., Ltd., Yangzhou Pharmaceutical Co., Ltd was absorbed and merged by Jiangsu Lianhuan Pharmaceutical Co., Ltd and Jiangsu Provincial Food and Drug Administration withdrew the company's drug production license in accordance with the provisions and cancelled it In addition, on January 9 and 10, Hubei Provincial Food and Drug Administration issued two announcements Hubei Xinye Pharmaceutical Co., Ltd was incorporated into Sinopharm holding Xinye (Hubei) Pharmaceutical Co., Ltd., while Wuhan Qingda Yuanzhi Pharmaceutical Co., Ltd was incorporated into Wuhan Baisen Pharmaceutical Co., Ltd It is understood that Hubei Xinye Pharmaceutical Co., Ltd and Wuhan Qingda Yuanzhi Pharmaceutical Co., Ltd comply with the relevant regulations and requirements of the merger and reorganization of drug distribution enterprises in Hubei Province, and allow the above two enterprises to apply for the cancellation of the "drug trade license" and the "drug trade quality management specification certificate" At the same time, the new application for drug business license and certificate of quality management standard for drug business of Sinopharm holding Xinye (Hubei) Pharmaceutical Co., Ltd., Wuhan BeiSen Pharmaceutical Co., Ltd were issued We have more than 4000 pharmaceutical companies now, and the number will drop significantly in the future According to the income and quantity distribution of pharmaceutical enterprises, the proportion of pharmaceutical enterprises with income less than 500 million yuan is as high as 81.58%, while the proportion of pharmaceutical enterprises with income more than 10 billion yuan is only 0.29% The small scale, slow accumulation and low technology content of Chinese pharmaceutical enterprises are important reasons Compared with the United States, the top 20 largest generic drug providers provide 95% of the market share of the United States, with a high degree of concentration In order to deal with the policy of 4 + 7 and two vote system, M & A among pharmaceutical enterprises has become the main way to survive: to find a new profit growth point through M & A If generic companies want to transform and upgrade, they will either do large-scale M & A or strengthen R & D For a group of small generic companies, generic drugs are different from innovative drugs, price reduction is an inevitable trend, and it is important to have cost advantage The data shows that the core of cost advantage is supply chain advantage If generic pharmaceutical enterprises want to have the advantage of scale, they can further reduce the cost through scale effect; and they need more approvals to facilitate the procurement of downstream enterprises and resist the increasingly fierce market competition Before that, the industry paid more attention to large-scale M & A of listed companies, but the development situation of unlisted pharmaceutical enterprises is also worth tracking and analyzing The announcement of Jiangsu Province and Hubei Province shows the efforts and actions of small-scale generic pharmaceutical enterprises to shuffle and upgrade At the same time that small-scale imitated pharmaceutical enterprises hold a group for warmth through M & A and restructuring, listed pharmaceutical enterprises need to deal with every decision prudently because of their large size, and more ways are taken to adjust marketing business, shrink R & D pipelines, reduce costs through layoffs, and sell assets to activate funds According to the statistics of industry analysts, pharmaceutical companies completed 39 asset sales in 2019, compared with 111 asset sales in 2017-2019 Since December, many well-known pharmaceutical enterprises, such as Haizheng pharmaceutical, Haier biology, humanwell pharmaceutical, Tianshili, Sihuan biology, Shuangcheng pharmaceutical and foci pharmaceutical, have successively issued asset sale announcements Haizheng Pharmaceutical Co., Ltd announced on January 7 that the auction of 5 apartments of the company located in block a, Junyue building, Jiaojiang District, Taizhou city was successful, with a total turnover of 1.82 million yuan Previously, Haizheng pharmaceutical had said that it had terminated 20 R & D projects due to the relationship of funds The company's R & D covers a wide range of product areas, including raw materials, generic drugs, biological drugs and innovative drugs On December 30, humanwell announced that it would sell its real estate in the new hospital area of Zhongxiang people's hospital to Xingrui assets The accumulated construction investment of the project is about 1 billion yuan, and the total sale price will be determined according to the final account audit results of the project According to preliminary calculation, the investment income of the project is about 40 million yuan Previously, humanwell medical intended to strengthen its strength in medical services through the acquisition of hospitals, which failed to achieve its goal, but put pressure on its business There are opinions in the industry: the sale of hospital related assets by humanwell pharmaceutical is also seen as a return to the past, focusing on the development of the main industry On December 16, Tianshili announced that the company plans to sell all its shares in Tianshili marketing company, and has signed a framework agreement with Chongqing pharmaceutical (Group) Co., Ltd on relevant matters.